Hormone-replacement therapy and cardiovascular diseases

New England Journal of Medicine

Volumn 349, Issue 6, 2003, Pages 521-522

  Bailar, John ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK BENEFIT ANALYSIS; CHEMICALLY INDUCED DISORDER; METHODOLOGY; NOTE; RISK;

CARDIOVASCULAR DISEASES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; RISK;

EID: 0041708046     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMp038110     Document Type: Review

References (6)

1. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50: the Framingham Study. N Engl J Med 1985;313:1038-43.
2. Stampfer MJ, Willett WC, Colditz GA, Rosner B, Speizer FE, Hennekens CH. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:1044-9.
3. Bailar JC III. When research results are in conflict. N Engl J Med 1985;313:1080-1.
4. Ware JH. The National Emphysema Treatment Trial - how strong is the evidence? N Engl J Med 2003;348:2055-6.
5. Idem. Interpreting incomplete data in studies of diet and weight loss. N Engl J Med 2003;348:2136-7.
6. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-50.